A new era in diabetic kidney disease therapy: toward remission and survival
Kidney Research and Clinical Practice · 28.10.2026 · 45 (6) · 849-851
DOI: 10.23876/j.krcp.26.213 ↗Kurz gefasst
Editorial in der Zeitschrift Kidney Research and Clinical Practice, erschienen am 28.10.2026. Verfasst von Eun Young Lee. Beteiligte Einrichtung: Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea. eylee@sch.ac.kr. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
four key therapeutic pillars: renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter-2 inhibitors (SGLT2i), nonsteroidal mineralocorticoid receptor antagonists (nsMRAs), and incretin-based therapies. Together, these strategies aim to slow DKD progression, achieve DKD remission, and improve patient survival through implementation tailored to regional healthcare systems, available resources, and patient populations. Figure illustration created with assistance from ChatGPT (OpenAI), with final content review and editing performed by the author.
Autor:innen und Institutionen
- Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Republic of Korea. eylee@sch.ac.kr.
Zitieren
APA
Lee, E. Y. (2026). A new era in diabetic kidney disease therapy: toward remission and survival. Kidney Research and Clinical Practice, 45(6), 849-851. https://doi.org/10.23876/j.krcp.26.213
Vancouver
Lee EY. A new era in diabetic kidney disease therapy: toward remission and survival. Kidney Research and Clinical Practice. 2026;45(6):849-851. doi:10.23876/j.krcp.26.213
BibTeX
@article{Lee2026,
author = {Lee, Eun Young},
title = {A new era in diabetic kidney disease therapy: toward remission and survival},
journal = {Kidney Research and Clinical Practice},
year = {2026},
volume = {45},
number = {6},
pages = {849--851},
doi = {10.23876/j.krcp.26.213}
}
EUVIMED